Novo Nordisk's Wegovy receives approval to fight heart disease.

On Friday, March 8, 2024, the US Food and Drug Administration (FDA) approved Novo Nordisk's weight loss medication, #Wegovy, for use in fighting heart disease. The 17,500-patient, multicenter, double-blinded, randomized, placebo-controlled, event-driven superiority trial (a.k.a. SELECT trial) demonstrated that Wegovy has a significant health benefit beyond shedding weight and managing blood sugar levels. The SELECT trial results indicate that weekly injections of Wegovy significantly reduced heart attack risk, stroke and death from cardiovascular causes by 20%. Read more from the American College of Cardiology here and access the New England Journal of Medicine article here. Explore the clinical trial details here, NCT03574597.